Brano Therapeutics
Singapore biotech spun out of Duke-NUS Medical School and launched in 2025 to develop therapies for cardio-metabolic disease; its lead asset is a small-molecule inhibitor that restores a metabolic pathway to treat heart failure with preserved ejection fraction (HFpEF), a condition with few effective treatment options.
Headquarters
Singapore
Year Founded
2025
Founders
Langdon Wu (CEO), Yibin Wang (scientific founder)
Country
Singapore
Financial Information
Funding Stage
Seed
Recent Funding
$6.8M
Funding By
Trinity Innovation Bioventure Singapore (TIBS), SEEDS Capital, SGInnovate, Duke-NUS LIVE Ventures
Core Technology
Small-molecule metabolic pathway restoration licensed from Duke-NUS Medical School
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Licensed from Duke-NUS Medical School
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
Duke-NUS Medical School (licensing and research partnership)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Metabolic approach to HFpEF, where treatment options remain limited